P TB PT

 A

For a 9-month-old boy with a positive Mantoux test of 10mm, a history of BCG vaccination, and coming from Myanmar, it's crucial to follow the UK NICE guidelines for tuberculosis (TB) management in children.

Key points for management in this case:

1. Risk Assessment

• Travel history: The child has a history of coming from Myanmar, a country with a higher TB burden. This is a significant risk factor.

• BCG vaccination: BCG vaccination is not considered protective against latent TB infection (LTBI) but may cause a false positive Mantoux test.

• Mantoux test: A positive test result (10mm induration) may indicate latent TB, especially in a child from a high-prevalence country. The child is at higher risk due to exposure in a TB-endemic region.

2. Diagnostic Evaluation

• Chest X-ray: Perform a chest X-ray to rule out active TB. Children with latent TB usually have normal chest X-ray findings.

• Examine for Symptoms: Assess for signs of active TB such as:

  • Cough, weight loss, fever, and night sweats.

  • If the child has any symptoms of active TB, further investigations, including microbiological testing (e.g., sputum, gastric aspirates if possible), would be needed.

3. Diagnosis of Latent TB (LTBI)

• Mantoux test: Positive Mantoux (≥10mm) in this case is highly suggestive of latent TB infection. A positive Mantoux test is interpreted with caution in a child who has received the BCG vaccine.

• Alternative Tests: Consider Interferon-Gamma Release Assay (IGRA), such as the T-SPOT.TB or Quantiferon-TB Gold test. These tests are more specific than the Mantoux test, particularly in individuals who have been vaccinated with BCG.

4. Treatment for Latent TB

• If no evidence of active TB is found (based on chest X-ray and clinical examination), the child should be started on treatment for latent TB.

  The treatment regimen for latent TB in children is typically:

  • Isoniazid (INH) 10-15 mg/kg/day for 6 months or

  • Rifampicin (RIF) 10 mg/kg/day for 4 months (if INH resistance is suspected, or if there's a risk of drug interactions with other medications).

  Note that isoniazid therapy requires monitoring for hepatotoxicity, especially in young children.

5. Follow-up and Monitoring

• Monthly monitoring: Ensure regular follow-up to monitor for any signs of active TB during treatment.

• Liver function tests: Perform baseline liver function tests and monitor for any hepatotoxic effects during isoniazid therapy.

6. Public Health Notification

• Notify local public health authorities for appropriate contact tracing and surveillance, especially given the child’s travel history.

7. Referral

• If there’s uncertainty regarding the diagnosis or management, refer to a pediatric TB specialist or infectious disease expert for further evaluation and treatment guidance.

Conclusion:

For a 9-month-old boy with a positive Mantoux test, BCG vaccination, and a history of travel from Myanmar, careful evaluation is needed to rule out active TB and confirm whether the child has latent TB infection. If the diagnosis of latent TB is confirmed, the child should be started on a course of isoniazid or rifampicin as per NICE guidelines.